Dr. Stacey Adam is an Vice President of Science Partnerships at the FNIH, leading many public-private partnerships, such the Cross-HHS Data Aggregation Initiative; RECOVER-Treating Long COVID (TLC); Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV); the Biomarkers Consortium; Accelerating Medicines Partnerships (AMPs); Partnership for Accelerating Cancer Therapies (PACT); and the Lung Master protocol (Lung-MAP) clinical trial. She has also led and assisted numerous project design phase teams during her tenure at the FNIH, including Pediatric Medical Device-PPP, Ultra-rare Tumor Treatment Advancement (ULTRA) Program; the Novel Alternative Methodologies (NAMs) Validation and Qualification Network (VQN) that are currently in process. Prior to FNIH, Dr. Adam was a Manager at Deloitte Consulting in the Federal Life Sciences and Healthcare Strategy practice where she supported many federal and non-profit client projects. Before Deloitte, Dr. Adam conducted her postdoctoral fellowship at Stanford University School of Medicine, where she was both an NIH and American Cancer Society supported fellow, and she earned her Ph.D. in Pharmacology with a Certificate in Mammalian Toxicology from Duke University.